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Abstract
Background: Human papilloma virus (HPV) infection was the main cause of cervical cancer. There were only a few reports
and detailed data about epidemiological research of HPV infection in rural population of China.
Materials and Methods: The cervical cells of rural Chaozhou women were collected, and multiplex real time PCR was firstly
performed to detect high-risk HPV (HR-HPV) infection, which could detect 13 types of HR-HPV (types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, and 68). Then, HPV-positive samples were typed by HPV GenoArray test.
Results: HR-HPV DNA was detected by multiplex real time-PCR in 3830 of 48559 cases (7.89%). There was a peak incidence
in age of 55–60 years group, and a lower incidence in who lived in plain group compared with suburban, mountain and
seashore group. 3380 cases of HPV positive sample were genotyped, 11.01% (372/3380) cases could not be classified,
among the typed 3008 cases, 101 cases were identified without HR-HPV type infection, 2907 cases were infected with one
HR-HPV type at least, the 6 most common HR-HPV types in descending order of infection, were type 52 (33.4%, 16 (20.95%),
58 (15.93%), 33 (9.94%), 68 (9.22%) and 18 (8.36%). The combined prevalence of HPV types 16 and 18 accounted for 28.52%
of total infection. However, type 52 plus 58 presented 48.23% of total infection. 2209/2907 cases were infected with a single
HPV type and 698/2907 cases were infected with multiple types, and multiple infection constituent ratio increased with age,
with a peak incidence in age 55–60 years group.
Conclusions: Our findings showed low prevalence of HPV vaccine types (16 and 18) and relatively high prevalence of HPV-
52 and -58, support the hypothesis that the second-generation HPV vaccines including HPV-52 and -58 may offer higher
protection for women in rural Guangdong Province.
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Introduction
Cervical cancer is the second most common cancer in women,
about 200 000 deaths yearly are caused by cervical cancer in the
world [1]. Therefore, the social consequences of this disease are
still tremendous. Certain types of human papillomavirus (HPV)
are now recognized as the main cause of cervical carcinoma [2].
At present, more than 100 HPV genotypes have been molecularly
characterized [1]. According to previous report, HPV-16, -18, -31,
-33, -35, -39, -45, -51, -52, -56, -58, -68, -69, -73, -59 and -82 were
classified as ‘‘high-risk types’’, associated with cervical cancer,
while HPV-6, -11 -42, -43 and -44 were classified as ‘‘low-risk
types’’ [2,3]. The development of a prophylactic vaccine against
these infections now appears to be the most promising way of
controlling cervical neoplasia. There are two licensed HPV
vaccines; Gardasil (HPV-6/11/16/18) and Cervarix (HPV-16/
18), mainly against the two major cancer-causing types (HPV-16/
18). These vaccines could also reduce the economic burden
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32149associated with HPV-related benign lesions, and these vaccines are
safe, well tolerated and highly immunogenic [4]. Clinical trials
have shown apparently type-restricted protective efficacy for
genital lesions related to targeted types in women who were naive
to the respective types at enrollment [4–8]. Since limited cross-
protection could be offered between HPV types [9], heterogeneity
in HPV type-specific distribution from different populations
should be taken into account when predicting the effect of current
prophylactic vaccines and forming the basis for the second-
generation vaccines targeted to specific regions [10].
To the best of our knowledge, no epidemiologic data on HPV
genotypes in general female population from rural area was
reported from Guangdong Province, southern China, which
highlights the need for timely population-based study in this
region. Due to the accessible anatomic site for sample collection
and the well-established sample collecting method for cervix, we
investigated the cervical HPV infection in asymptomatic, general
female population to understand the overall, type-specific, age-
specific HPV prevalence and extent of multiple infections in rural
Guangdong Province.
Methods
Study subjects
From December 2009 to September 2010, an epidemiologic
screening for HPV infections was organized by Chaozhou
municipal government, with the cooperation of gynaecological
practitioners in 13 hospitals (Chaozhou Central Hospital,
Chaozhou People’s Hospital, Chaozhou Gynecological and
Pediatric Hospital, Chao’an County Gynecological and Pediatric
Hospital, Fengxi District Hospital, Raoping County People’s
Hospital, Raoping Huaqiao Hospital, Xinfeng People’s Hospital,
Qiaodong Hospital, Yixi Hospital, Chengxi Hospital, Fengxin
Hospital and Raoping County Gynecological and Pediatric
Hospital).
The population in rural Chaozhou eligible to this study included
about 300000 women (aged from 35 to 60 years). The majority of
eligible population refused to participate mainly because they did
not have enough time or did not think they needed a gynecological
examination in the absence of symptoms. A woman was eligible to
be study subject if she: (a) was mentally and physically competent;
(b) was aged between 35 and 60 years; (c) was a permanent resident
of local area; (d) had no history of abnormal cytology or cervico-
vaginal dysplasia; (e) had no history and associated symptoms of
other HPV-related diseases; (f) had given birth at least once; (g) was
not presently pregnant; (h) had not undergone a total uterus or
cervix resection; (i) was willing to undergo HPV testing.
Study design
Eligible women were invited for a face-to-face interview, and a
socio-demographic characteristics based questionnaire was de-
signed to collect information on lifestyle, menstrual status,
reproductive history, contraception and sexual behavior. Written
informed consent was obtained by signature or thumbprint. After
the interview, all women underwent a gynecological examination
performed by gynaecological practitioners in their village clinics or
in 13 above-mentioned hospitals, exfoliated cervical cells were
collected for HPV DNA detection. Multiplex real time polymerase
chain reaction (PCR) was firstly performed to detect high-risk
HPV infection in 3 hospitals (Chaozhou People’s Hospital,
Raoping County People’s Hospital, Chao’an County Gynecolog-
ical and Pediatric Hospital). Then, HPV GenoArray test was used
to detect the specific HPV subtypes with the same HR-HPV
samples in Hybribio Limited Corporation, Chaozhou, China.
HPV DNA positive cases for real time-PCR were advised to
receive liquid-based cytology test (LCT), and histological diagnosis
was performed if necessary. Most confirmed or highly suspicious
high grade or invasive lesions were treated at the collaborating
hospitals with loop excision, surgical conization, hysterectomy, or
radiotherapy, according to local protocols. The screening and the
following cytology test were provided at no cost to the participant.
All studies were approved by Chaozhou Central Hospital Ethics
Committee. The designed details were shown in Figure 1.
Groups
Chaozhou region is a place in easternmost Guangdong province
of the People’s Republic of China. It borders Shantou to the south,
Jieyang to the southwest, Meizhou to the northwest, the province
of Fujian to the east, and the South China Sea to the southeast. It
is administered as a prefecture-level city with a jurisdiction area of
3,614 square kilometers and a total population of 2,600,000.
Chaozhou’s municipal region includes a city (Xiangqiao District
and Fengxi District) and two county (Chao’an and Raoping
County), with 840 natural villages (Figure 2).
For age prevalence, the eligible subjects were divided into 5 age
groups with five-year interval, the actual age of each subject was
counted with the formula: (interview data-birthday)/365.25 by
Microsoft Excel software. For area prevalence, the eligible subjects
were divided into 4 area groups and 41 clusters of natural villages,
including suburban (2 clusters of villages), plain (18 clusters of
villages), mountain (16 clusters of villages) and seashore (5 clusters
of villages) (Figure 2) according to their living area.
Cervical specimen collection and HPV DNA extraction
Samples of exfoliated cervical cells were collected using plastic
cervical swabs. The sampler was inserted 1–1.5 cm into the
endocervical canal and rotated 4–5 full turns in counter-clockwise
direction. The tip containing cellular material was then placed into
transport medium tube and stored at 4uC immediately. All
specimens were coded without knowledge of the subjects. All swabs
and store bottle with specimen transport medium were from
Hybribio Biotechnology Limited Corp., Chaozhou, China. All
specimenswerefinallysentto3 clinicalPCR laboratories (Chaozhou
People’s Hospital, Raoping County People’s Hospital, Chao’an
County Gynecological and Pediatric Hospital) for HPV analysis.
The brush and supernatant were removed after the cells were
centrifugated for 5 mins with relative centrifugal force 960 g.D N A
was extracted from the sediments with alkaline lysis method Kits
(Hybribio Biotechnology Limited Corp.), resuspended in 100 mL
elution buffer, and ready for PCR or stored at 220uC [11,12].
Real time-PCR for HR-HPV DNA
High-risk HPV (HR-HPV) infection was detected in an ABI
Stepone thermal cycler with multiplex real time-PCR, the
amplification was performed according to manufacture’s protocol
(Hybribio Biotechnology Limited Corp., Chaozhou, China).
The kits of real time PCR could detect 13 types of HR-HPVs
infection (16,18,31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), but
could not type.
HPV GenoArray test
HPV GenoArray test was performed for HR-HPV positive
samples with the same DNA as for real time PCR. Genotyping for
HPV was done by DNA amplification, flow-through hybridization
and gene chip by HybriMax (Chaozhou Hybribio Limited Corp.,
Chaozhou, China). Test was performed according to the
manufacture’s instructions. Detailed protocols for this assay had
Human Papillomavirus Infection in Rural China
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specific oligonucleotides immobilised on a nylon membrane. The
chip could identify 13 high-risk HPVs (HR-HPVs) (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59 and 68), five low-risk HPVs (LR-
HPVs) (6, 11, 42, 43, 44) and popular HPV type 53, 66 and
CP8304 in Chinese population. The final results were detected by
colorimetric change on the chip under direct visualization.
Liquid-based cytology test (LCT) and pathological
diagnosis
HPV DNA positive cases for real time-PCR were advised to
receive LCT, which was performed in 3 hospitals (Chaozhou
Central Hospital, Raoping People’s Hospital and Chaozhou
Gynecological and Pediatric Hospital). The women were called
back and exfoliated cervical cells were collected, mixed with 3 mL
specimen stored liquid (Hybribio, Chaozhou, China) and stored in
room temperature. The specimens were sent to 3 above-
mentioned hospitals for LCT analysis. The results were evaluated
using the Bethesda system [13]. The evaluation system included: (i)
negative, (ii) atypical squamous cells (ASC), (iii) low-grade
squamous intraepithelial lesion, (iv) high-grade squamous intra-
epithelial lesion, and (v) squamous cell carcinoma.
The abnormal LCT cases were further advised to receive
colposcopy and biopsies, all of cases with CIN 2, 3, invasive cancer
or carcinoma in situ received loop excision, surgical conization,
hysterectomy, or radiotherapy according to local protocols.
Statistical analysis
All of data was analyzed by SPSS version 16 software. Chi-
square test was used to assess HPV DNA infection rate in
Figure 1. Enrollment and outcomes.
doi:10.1371/journal.pone.0032149.g001
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used to assess the relationship between age and multiple HPV
type infection constitute ratio. Statistical significance was
accepted if the P value was 0.05 or less. All P values were two-
sided.
Results
Prevalence of HR-HPV
At this program initiation, a total of 49458 women participated
in the study, and finished the questionnaire, but 899 women did
not meet the inclusion criteria and were excluded, mainly due to
their age or total uterus or cervix resection (Figure 1).
Among 48559 eligible rural Chaozhou women, real time-PCR
revealed that 3830 cases were positive for HR-HPV DNA, and the
crude infection rate was 7.89% (3830/48559) (Figure 1).
Age from 35 to 55, the prevalence of HR-HPV ranged from
7.28% to 7.88%, were all lower than the crude infection rates of
7.89%, there was no significant difference statistically between
each group (P.0.05). However, the HR-HPV infection rate of age
55–60 group (9.39%) was significantly higher than those of the
other 4 groups (P,0.001) (Table 1, Figure 3). Different from our
previous report [12], the prevalence did not present a constantly
increasing trend with age, instead of an infection peak at the oldest
group (Figure 3A).
Women lived at the seashore had the highest prevalence of
HR-HPV, the second was those lived in the mountain, the third
was who lived in the suburban. The HPV infection rate in these
three areas decreased from 9.61% to 8.45%, even though, it was
still higher than the crude infection rates of 7.89%, and there was
Figure 2. The topographic map of Chaozhou area. plain (green), suburban (pink), seashore (blue) and mountain (orange).
doi:10.1371/journal.pone.0032149.g002
Table 1. Specific age-related prevalence for HR-HPV.
Age group Total cases
Mean age
(years)
HR-HPV
positive cases Prevalence
no.  X X+s no. %
35–40 9704 37.7961.32 719 7.41
40–45 10920 42.5561.45 856 7.84
45–50 10168 47.1861.33 801 7.88
50–55 10151 52.5561.39 739 7.28
55–60 7616 57.1661.46 715 9.39*
Total 48559 46.9566.78 3830 7.89
%=no. of HR-HPV positive cases/no. of total cases.
*The HR-HPV infection rate of women aged 55–60 group was significantly
higher than those of the other 4 groups.
doi:10.1371/journal.pone.0032149.t001
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Exclusively, the HPV prevalence of women lived in the plain
(7.31%) was lower than the crude infection rate, and was
significantly lower than the other three groups (P,0.01) (Table 2,
Figure 3B).
Specific age-related prevalence was also observed in women
who lived in the suburban, plain and mountain, there was an
infection peak at the age from 55 to 60 years. However, there was
a great different prevalence in women who lived at the seashore,
herein, the HR-HPV infection rate increased in age from 35 to 50
years, and decreased in the elders (Figure 3C).
Specific Prevalence of HR-HPV Types
3380 HR-HPV positive cases received HPV GenoArray test,
372 cases (11.01%, 372/3380) did not hybridize with any probes
(21 subtypes), were coded as HPV type X. Among the typed 3008
cases, 101 cases were identified without HR-HPV type infection,
and specific HR-HPV types were detected in 2907 cases, among
them, 2209 cases (75.99%) were infected with a single HR-HPV
type, and 698 cases (24.01%) were infected with multiple types
(Figure 1).
Consistent with our previous report [12], type 52 was the most
common HR-HPV type, more than one third cases (33.40%) were
infected with this type (including simple infection and multiple
infections). The other 5 most common HR-HPV types in
descending order, were types 16 (20.95%), 58 (15.93%), 33
(9.94%), 68 (9.22%) and 18 (8.36%) (Table 3).
In these 2907 HR-HPV typed cases, each HPV types presented
a unique age-related prevalence, we could not find any incidence
peak at the elder group corresponding to the prevalence of HR-
HPV for real time PCR. Similarly, there was no lower incidence in
women lived in the plain than those of the other three areas
(Table 4 and 5). The age and area prevalence of the 6 most
common HR-HPV types was shown in Figure 4 A and B.
The combined prevalence of HPV types 16 and 18 accounted
for 28.52% of total HR-HPV infected cases. However, type 52
plus 58 presented 48.23% of total HR-HPV infected cases.
Interestingly, the prevalence of HPV type 16 and 18 decreased
slowly with age increasing, while the type 52 and 58 increased with
age increasing (Figure 4C).
HR-HPV typically infected with a single type (Figure 5A), as
described previously, more than three quarter (75.99%) genotyped
cases were single infection. For multiple HPV infections, double
infections was the major multiple infections, nearly three quarter
(72.78%, 508/698) of multiple infection cases were double
infections. About one fifth (139/698) cases were triple infections,
and only 7% of cases were infected with four or more different
HPV subtypes. At most, several cases were infected with seven
different subtypes. The prevalence of infection frequency was
shown in Figure 5B.
The most common infection type participated in the most
common multiple infection state, for example, the type 52
combined with type 16 was the most common double infections.
The main multiple HR-HPV infection types were shown in
Table 6.
Furthermore, we found out that the multiple infections
constituent ratio increased with age, and there was a linear
regression relationship, the Square R was 0.783, and the linear
regression equation was: Y=20.054+0.006X (Figure 5C). This
kind of trend was also observed in women who lived in the
suburban, plain and mountain. For women lived at the seashore,
this kind of trend was found in age from 35 to 50, an incidence
peak appeared in age from 50 to 55, and decreased in the elders.
(Figure 5 D). But there was not significant difference for the
multiple infections constituent ratio in 4 different areas (Figure 5E).
Furthermore, this kind of age and area related prevalence was also
Figure 3. The HR-HPV prevalence. A: The prevalence of HR-HPV in
5 different age groups. B: The prevalence of HR-HPV in 4 different area
groups. C: Specific age-related prevalence of HR-HPV infection in 4
different areas.
doi:10.1371/journal.pone.0032149.g003
Table 2. Specific area-related prevalence for HR-HPV DNA.
Area group
Total
cases
Mean age
(years)
HR-HPV
positive cases Prevalence
no.  X X+s no. %
Suburban 9170 47.3566.92 775 8.45
Plain 31717 46.7266.80 2320 7.31*
Mountain 6201 47.5966.40 593 9.56
Seashore 1457 46.7566.77 140 9.61
Total 48545 46.9566.78 3828 7.89
%=no. of HR-HPV positive cases/no. of total cases.
*The HR-HPV infection rate of women lived in the plain was significantly lower
than those of the other 3 groups.
doi:10.1371/journal.pone.0032149.t002
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68 and 18 (Figure 5F and 5G).
Cytology test, diagnosis and treatment
A total of 2077 women infected with specific HR-HPV types
received LCT. 12.3% (255/2077) women who had abnormal
LCT received histological diagnosis, pathological abnormalities
(CIN1 or above) were detected in 60.39% (154/255) women. A
total of 67 cases with CIN3 or above were identified and they
received appropriate treatment in hospitals. Among them, 26
(38.8%) cases were infected with HPV-16, 2 (3.0%) cases were
infected with HPV-18, 2 (3.0%) cases were infected HPV-52, 3
(4.5%) cases were infected with HPV-58, the others (34 cases,
38.8%) were all multiple infection cases or infected with above not
mentioned subtypes. Nearly 150 women infected with type X
received LCT and 4 women were detected with pathological
abnormalities (3 cases of CIN1 and 1 case of CIN2) and we did not
detect CIN3 or above in type X group.
Discussion
Until recently, a large-scale HPV testing for cervical cancer
screening has been performed in China, based on the technology
of Hybrid Capture II(HC- II) [14]. Real time multiplex PCR for
HR-HPV test (Hybribio, China), which has already been used for
quite a while in China, showed high level agreement with HC-II
[15,16]. With the support of local government, we organized a
large-scale HPV testing for cervical cancer screening in rural
Chaozhou based on the real time multiplex PCR. Considering
that Real time multiplex PCR test could not identify genotypes, we
utilized a GenoArray (Hybribio, China) for the detection of 21
HPV subtypes popular in Chinese, including 13 types of
established HR-HPV.
Compared with similar studies in China, HR-HPV prevalence
(7.8%) in rural Chaozhou of Guangdong Province was similar to
that in Tibet (7.05%) [17], was also similar to Macao [18] and our
previous study of urban women in Chaozhou (6.52%) [12], but
lower than that in Beijing of north China (9.9%) [19], Zhejiang
Province of southeast China [20], and an urban city in south
China (17.6%) [21]. In Chaozhou rural area, about 300000
women between 35 and 60 years were eligible for this time
screening. Although only about 20% of women participated, it
may not cause large bias as HPV infection is asymptomatic and
nearly 50000 (20%) samples was large enough [19]. The
population in our study was asymptomatic women with no history
of cervical neoplasia or other HPV-related diseases. Based on cost
constraints, we did not perform the Bethesda System Terminology
Table 3. The prevalence of 13 HR-HPV subtypes.
HPV type Single infection Multiple infections Total
no. % no. % no. %
52 654 22.50 317 10.90 971 33.40
16 397 13.66 212 7.29 609 20.95
58 310 10.66 153 5.26 463 15.93
33 153 5.26 136 4.68 289 9.94
68 146 5.02 122 4.20 268 9.22
18 150 5.16 93 3.20 243 8.36
31 98 3.37 92 3.16 190 6.54
39 115 3.96 58 2.00 173 5.95
59 55 1.89 41 1.41 96 3.30
51 44 1.51 25 0.86 69 2.37
56 39 1.34 24 0.83 63 2.17
35 26 0.89 21 0.72 47 1.62
45 22 0.76 24 0.83 46 1.58
Total 2209 75.99 688 24.01 2907 100
%=no./2907 (the total number of HR-HPV typed cases).
HR-HPV type was arranged by the descending order of infection rate.
doi:10.1371/journal.pone.0032149.t003
Table 4. Specific age-related prevalence for each HR-HPV type.
HR-HPV
Type Age 35–40 Age 40–45 Age 45–50 Age 50–55 Age 55–60
no. % no. % no. % no. % no. %
52 191 33.75 222 33.38 180 29.27 182 34.47 196 36.77
16 113 19.96 152 22.86 138 22.44 106 20.08 100 18.76
58 75 13.25 89 13.38 106 17.24 88 16.67 105 19.70
33 48 8.48 58 8.72 70 11.38 47 8.90 66 12.38
68 48 8.48 55 8.27 46 7.48 58 10.98 61 11.44
18 52 9.19 56 8.42 52 8.46 42 7.95 41 7.69
31 40 7.07 50 7.52 43 6.99 27 5.11 30 5.63
39 41 7.24 45 6.77 27 4.39 30 5.68 30 5.63
59 16 2.83 25 3.76 22 3.58 15 2.84 17 3.19
51 13 2.30 15 2.26 15 2.44 13 2.46 13 2.44
56 10 1.77 14 2.11 10 1.63 17 3.22 12 2.25
45 10 1.77 12 1.80 9 1.46 9 1.70 6 1.13
35 14 2.47 11 1.65 5 0.81 10 1.89 7 1.31
%=no./the total number of HR-HPV typed cases in each age group.
Simple and multiple infections were all included in each age group.
doi:10.1371/journal.pone.0032149.t004
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women received cytology test.
The most common HR-HPV subtypes in general women
population worldwide were HPV-16, -18, -31, -58, -52, -51 and -33,
while the rank varied by area [22]. Contrasting to most previous
studiesinChina[19,21,23,24]and otherpopulations[22],HPV-52,
rather than HPV-16, was the most commonly identified type in our
rural population (33.40% of all typed cases), consistent withthe data
from Guangzhou [25], Chaozhou city [12], Macao [18], Zhejiang
province of China [20] and Japan [26]. HPV-16 ranked the second
and the prevalence (20.95% of all typed cases) was comparable with
that worldwide [22]. HPV-52 was more prevalent than HPV-16,
this result may be due to the geographical and biological
interplay between HPV types and host immunogenic factors
[22,27]. Another interpretation might attribute to the genotyp-
ing system [28,29]. HPV-58, another common type in Asian
population [18,25], ranked the third (15.93% of all typed cases),
similar to that in Japan [26]. An interesting point was HPV-68,
not very common in other researches [3,4,22], ranked the sixth
in our study, revealed the special distribution of HR-HPV in
rural population of Chaozhou.
In our previous study, we found that HPV-52 and -58 were the
most prevalent genotypes in Chinese women in Guangdong
Province with HPV GenoArray-test kit [12]. Liu et al. reported
that HPV GenoArray-test had a good sensitivity in detection of
HPV-52, could also detect HPV-16 and -18 in as few as 10–50
copies [29]. The GenoArray-test and Roche Linear Array (LA)
HPV genotyping assays showed no significant difference in the
rates of detection of HPV genotypes, and the interassay agreement
was excellent [29]. In addition, our subsequent sequencing studies
suggested that GenoArray was a convincing method for
genotyping (data not shown). Therefore, the preponderance of
HPV-52 and -58, accounting for 48.23% of all infections in our
study population, is very meaningful and convincing.
The screening included a round of real-time PCR detection for
HR-HPV, and gene typing of a large sample of subjects for 13
subtypes of HR-HPV. However, there were 372 HPV DNA
positive cases that could not be genotyped by GenoArray test (type
X). We speculate that the most possible reason come from the
difference between the sensitivity of real-time PCR and GenoAr-
ray test, the claimed sensitivity by manufacturer was 50 copies for
the former, while 300 copies for the latter. Actually, we found that
the mean cycle threshold (CT) value of these type X cases was
much higher than the typed cases (data not shown). Therefore, we
believed that the main reason for these type X cases was that they
were infected with a relatively lower viral load.
For the current available prophylactic vaccines, the prevalence
of vaccine types (HPV-16 and HPV-18) was consistently low
across age groups in our study (28.52% of total typed cases). As our
study had shown that HPV-52 and -58 were predominant in rural
populations of Chaozhou, more prevalent than HPV-16 and -18,
and we assume that the second-generation HPV vaccines
including HPV-52 and -58 may provide higher protection for
female in Chaozhou.
Bimodal age distribution of HR-HPV, which was common in
previous studies [24,25], was not observed in the current study.
Older women (55–60 years old) in the Chaozhou rural area had
the highest infection and the second was 50–55 years old group,
suggesting a higher possibility of acquiring HPV infections at older
ages [12].
As HPV is often acquired soon after sexual initiation [4,5], the
actual first peak of HR-HPV infection might before 20 years old,
the age group not included in our research. Furthermore, older
women (55–60 years old) in the Chaozhou rural area had the
highest multiple infections and the multiple prevalence increased
with age, there was linear regression relationship between
multiple infections constituent ratio and age. The infection peak
observed in older women of our study may be partly explained by
viral persistence or reactivation of latent HPV due to the
physiologic and immunologic disorder caused by hormone
fluctuations at menopausal transition [12,27]. HR-HPV positivity
at the age of 55–60 years implies more possibility of viral
persistence, which makes HPV screening more meaningful for
older women than for younger women. For older female with
positive HR-HPV, further evaluation, including cytology and
even colposcopy, should be considered and regular screening
Table 5. Specific area-related prevalence for each HR-HPV type.
HR-HPV
Type Suburban Plain Mountain Seashore
no. % no. % no. % no. %
52 178 29.92 631 34.75 130 32.10 32 35.96
16 111 18.66 390 21.48 85 20.99 21 23.60
58 114 19.16 271 14.92 70 17.28 8 8.99
33 60 10.08 174 9.58 48 11.85 7 7.87
68 43 7.23 176 9.69 39 9.63 10 11.24
18 47 7.90 149 8.20 37 9.14 10 11.24
31 52 8.74 109 6.00 24 5.93 5 5.62
39 41 6.89 106 5.84 19 4.69 7 7.87
59 20 3.36 56 3.08 14 3.46 5 5.62
51 15 2.52 43 2.37 8 1.98 3 3.37
56 16 2.69 39 2.15 8 1.98 0 0.00
45 13 2.18 22 1.21 8 1.98 3 3.37
35 13 2.18 28 1.54 3 0.74 3 3.37
%=no./the total number of HR-HPV typed cases in each area group.
doi:10.1371/journal.pone.0032149.t005
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32149Figure 4. The prevalence of common infection HR-HPV subtypes in rural Chaozhou. A: The age-related prevalence of the 6 most common
HR-HPV subtypes. For HPV subtypes 52, 16, 58, 33, 68 and 18, there was not apparent peak infection incidence in specific age group. B: The area-
related prevalence of the 6 most common HR-HPV subtypes. For HPV subtypes 52, 16, 58, 33, 68 and 18, there was not any incidence difference
statistically in women who lived in 4 different areas. C: The age-related combined prevalence of the type 16 plus 18, and type 52 plus 58.
doi:10.1371/journal.pone.0032149.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32149Figure 5. Simple/multiple infection composition. A: Simple/multiple infection constituent ratio of HR-HPV subtypes. B: The case numbers of
infection frequency. The case number sharply decreased with the increasing of infection frequency. C: Linear regression relationship between
multiple infections constituent ratio and age. The mean age of each group was 37.8261.31, 42.4761.47, 47.1761.33, 52.6061.41 and 57.1361.43
years, respectively. The multiple infections constituent ratio increased with age. D: The age-related multiple infections constituent ratio in 4 different
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development of cervical cancer.
We also explored the effect of living area for HR-HPV
infection, 4 kinds of typical living place were divided, including
suburban, plain, seashore and mountain. There was significant
difference between the incidence of plain and those of other 3
groups. suburban people lived neighborhood with city people, they
were heavily influenced by city people, their incidence was also
similar to the same city women [12]. In Chaozhou rural plain,
because their well-developed industries, peoples here worked at
their villages and seldom went out for work. However, at the
seashore and mountain area, there were a lot of villagers work far
away from their home (data not shown), that made husband and
their wife separate, provide the opportunity for ex-marriage sex,
that increase the infection possibility of HPV, because in areas
where women’s sexual conception and behavior are conservative,
men possessing multiple sexual partners may be a predominant
resource for HPV infection in female as long as HPV is mainly
transmitted through sexual intercourse [30].
Previous studies showed that high-risk sexual behavior,
including early sexual initiation, multiple sexual partners and
sexual partner as an HPV carrier, was the vital factor for HPV
infection in women [20,31]. We also tried to explore the
independent predictors for categories of HPV positivity, however,
in rural Chaozhou, eastern Guangdong Province of China, a
traditional Confucian culture influential place, most women
refused to answer the question of sexual behavior, thus, we failed
to get independent indicators related with sexual behavior that
influenced the HPV infections.
HPV testing as a primary screening test for cervical cancer was
supported by several reports [14,26]. To our knowledge, this is the
first population-based study conducted in rural Guangdong of
areas. The multiple infections constituent ratio increased with age for women who lived in the suburban, plain and mountain. For those lived at the
seashore, there was an incidence peak in age from 50 to 55 group. E: The multiple infections constituent ratio in 4 different areas. There was no
significant difference in 4 areas. F: The percentage of multiple infections of the 6 most common HR-HPV subtypes in 5 different age groups. G: The
percentage of multiple infections of the 6 most common HR-HPV subtypes in 4 different area groups.
doi:10.1371/journal.pone.0032149.g005
Table 6. Prevalence of HPV multiple infections subtypes.
Multiple HPV infection types no. % Multiple HPV infection types no. %
Double infections 508 17.48 33 and 39 5 0.17
33 and 18 4 0.14
52 and 16 42 1.44 33 and others
1 19 0.65
52 and 58 19 0.65 68 and 18 3 0.10
52 and 33 19 0.65 68 and 39 2 0.07
52 and 68 18 0.62 68 and others
1 15 0.52
52 and 31 18 0.62 18 and 31 5 0.17
52 and 18 16 0.55 18 and 39 2 0.07
52 and 39 7 0.24 18 and others
1 15 0.52
52 and others
1 72 2.48 Other double infections 50 1.72
16 and 58 21 0.72 Triple infections 139 4.78
16 and 18 12 0.41
16 and 68 11 0.38 52, 68 and 31 6 0.21
16 and 33 9 0.31 52, 16 and 33 5 0.17
16 and 31 7 0.24 52, 16 and cp8304 5 0.17
16 and 39 5 0.17 52, 16 and 68 4 0.14
16 and others
1 39 1.34 52, 16 and 58 3 0.10
58 and 68 10 0.34 52, 16 and 39 3 0.10
58 and 33 10 0.34 52, 18 and cp8304 3 0.10
58 and 31 5 0.17 52, 31 and cp8304 3 0.10
58 and 18 4 0.14 52, 58 and 53 3 0.10
58 and 39 3 0.10 52, 68 and 53 3 0.10
58 and others
1 26 0.89 Other triple infections
2 101 3.47
33 and 31 9 0.31 Quadruple infections or more
3 51 1.75
33 and 68 6 0.21
%=no./2907 (the total number of HR-HPV infected cases).
1Others included the lowest prevalence 5 HR-HPV type 59, 51, 56, 35 and 45, and LR-HPV type 6, 11, 42, 43 and 44, as well as Chinese popular HPV type 53, 66, and
CP8304.
2Other triple infections were less than 3 cases.
3Two cases were infected with the same 4 subtypes (16, 18, 33 and 68), and two cases were infected with the same 5 subtypes (52, 56, 66, 68 and CP8304), the others
were different from each other in that, there was only one case for every subtype combination.
doi:10.1371/journal.pone.0032149.t006
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rapid, simple, and affordable and its accuracy has been found to be
substantially equivalent to the approach of using HC-II [15,16]. In
the context of successful establishment of a low-price, new real
time HPV-DNA testing platform, using single HPV testing alone
as the primary screening technology is promising in less developed
areas where the health care infrastructure cannot afford a
cytology-based screening system.
Conclusions
We report the results of a population-based HPV screening of
48559 women in a rural area of Guangdong Province of China.
The screening included a round of real-time PCR detection for
HR-HPV, and gene typing of a large sample of subjects for 13
subtypes of HR-HPV. The population-based nature of this study
provides previously un-available estimates of the prevalence of the
full spectrum of HPV infections in this rural area of China. The
cross-sectional information derived from this analysis, should aid
in the design of HPV vaccines. The data showed low prevalence of
available HPV vaccine types and relatively high prevalence of
HPV-52 and -58. Our findings support the hypothesis that the
second-generation HPV prophylactic vaccines including HPV-52
and -58 may offer higher protection for women in this rural area.
Furthermore, our data also support close surveillance of 55–60
year women with HR-HPV infection. Our HPV-DNA screening
trials could be easily performed and economically thrifty, will
probably be conducted in other rural populations of China.
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